rss
Br J Ophthalmol 2009;93:622-626 doi:10.1136/bjo.2008.151977
  • Clinical science
    • Original Article

Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration

  1. K Sayanagi,
  2. S Sharma,
  3. P K Kaiser
  1. Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Dr P K Kaiser, Digital OCT Reading Center, Cole Eye Institute, 9500 Euclid Avenue, Desk i3, Cleveland, OH 44195, USA; pkkaiser{at}aol.com
  • Accepted 14 December 2008
  • Published Online First 10 February 2009

Abstract

Aims: To evaluate the photoreceptor layer status after antivascular endothelial growth factor (VEGF) therapy in choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT).

Design: Prospective, consecutive case series.

Methods: Twenty-three eyes of 22 patients with CNV secondary to AMD with foveal thickness less than 250 µm after treatment with anti-VEGF therapy and no obvious leakage on time domain OCT, and eight healthy subjects as controls, were imaged with at least one of four different SD-OCT devices. The inner and outer segment (IS/OS) photoreceptor layers were graded, and correlated with various characteristics including visual acuity.

Results: The IS/OS layer was detected in eight eyes (35%) of patients with AMD and all eyes (100%) of the healthy control subjects (p = 0.002). Eyes in patients with AMD with preserved IS/OS had a significantly better BCVA and mean change in BCVA, and were more likely not to have had previous laser treatment compared with eyes with absent IS/OS.

Conclusions: SD-OCT is a useful tool to visualise IS/OS status. IS/OS is often absent in patients who have received treatment with anti-VEGF therapy for CNV due to AMD. The IS/OS status after anti-VEFG therapy correlates with BCVA and mean change in vision.

Footnotes

  • Competing interests: KS has no proprietary interest in any aspect of this report. SS has received travel funding from Reichert, Inc. PK has received honoraria from Carl Zeiss Meditec, Heidelberg Engineering, Novartis, Genentech, and QLT, and research grant support from Genentech, Novartis, OSI-Eyetech and QLT.

  • Ethics approval: Ethics approval was provided by the Cleveland Clinic Institutional Review Board.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.151977v1
    2. 93/5/622 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.